GSK is expected to achieve blockbuster status for its months-old RSV vaccine this week, stealing a march on rival Pfizer and begin allaying long-standing investor concerns about its pipeline.
More than a fifth of adults over 60 in the US have received a vaccine for respiratory syncytial virus — an infection with cold-like symptoms — in the months since GSK and US rival Pfizer rolled out the first vaccines across the US.
GSK’s vaccine generated ￡709mn of sales in the third quarter of 2023. Analysts have predicted that it hit the $1bn milestone at which drugs become “blockbusters” in the final quarter of the year. GSK will disclose sales figures when it reports full-year results on Wednesday.
您已閱讀17%（700字），剩余83%（3397字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。